Emergent Biosolutions Shares Rise 16% on Orders Secured for Smallpox, Monkeypox Vaccines

Dow Jones
2024-09-25
 

By Denny Jacob

 

Emergent Biosolutions shares climbed 16% after disclosing that it has secured about $400 million for this year and next for its portfolio of smallpox and monkeypox vaccine products.

Shares were trading around $7.08. The stock is up 55% on the year.

The company, which develops and manufactures medical countermeasures, said its secured orders include a previously disclosed U.S. government contract for smallpox and monkeypox vaccines, among other procurements. Customer orders of nearly $210 million have been delivered to date in 2024, it said.

 

Write to Denny Jacob at denny.jacob@wsj.com

 

(END) Dow Jones Newswires

September 25, 2024 08:04 ET (12:04 GMT)

Copyright (c) 2024 Dow Jones & Company, Inc.

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10